204 related articles for article (PubMed ID: 22069467)
1. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas.
Alonso MM; Diez-Valle R; Manterola L; Rubio A; Liu D; Cortes-Santiago N; Urquiza L; Jauregi P; Lopez de Munain A; Sampron N; Aramburu A; Tejada-Solís S; Vicente C; Odero MD; Bandrés E; García-Foncillas J; Idoate MA; Lang FF; Fueyo J; Gomez-Manzano C
PLoS One; 2011; 6(11):e26740. PubMed ID: 22069467
[TBL] [Abstract][Full Text] [Related]
2. A SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor development.
Benedetti V; Banfi F; Zaghi M; Moll-Diaz R; Massimino L; Argelich L; Bellini E; Bido S; Muggeo S; Ordazzo G; Mastrototaro G; Moneta M; Sessa A; Broccoli V
Sci Adv; 2022 Aug; 8(31):eabn3986. PubMed ID: 35921410
[TBL] [Abstract][Full Text] [Related]
3. LncRNA GSCAR promotes glioma stem cell maintenance via stabilizing SOX2 expression.
Jiang X; Zhang Y; Yuan Y; Jin Z; Zhai H; Liu B; Li Y; Zhang C; Chen M; Shi Y; Yan D; Pu J; Chen Y; Yang C
Int J Biol Sci; 2023; 19(6):1681-1697. PubMed ID: 37063420
[TBL] [Abstract][Full Text] [Related]
4. SOX2 downregulation of PML increases HCMV gene expression and growth of glioma cells.
Wen L; Wang XZ; Qiu Y; Zhou YP; Zhang QY; Cheng S; Sun JY; Jiang XJ; Rayner S; Britt WJ; Chen J; Hu F; Li FC; Luo MH; Cheng H
PLoS Pathog; 2023 Apr; 19(4):e1011316. PubMed ID: 37058447
[TBL] [Abstract][Full Text] [Related]
5. Differential sequences and single nucleotide polymorphism of exosomal SOX2 DNA in cancer.
Vaidya M; Sugaya K
PLoS One; 2020; 15(2):e0229309. PubMed ID: 32092088
[TBL] [Abstract][Full Text] [Related]
6. SWIM tool application to expression data of glioblastoma stem-like cell lines, corresponding primary tumors and conventional glioma cell lines.
Fiscon G; Conte F; Paci P
BMC Bioinformatics; 2018 Nov; 19(Suppl 15):436. PubMed ID: 30497369
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of SOX2 Gene by Histone Modifications: SOX2 Enhances Human Prostate and Breast Cancer Progression by Prevention of Apoptosis and Enhancing Cell Proliferation.
Kar S; Niharika ; Roy A; Patra SK
Oncology; 2023; 101(9):591-608. PubMed ID: 37549026
[TBL] [Abstract][Full Text] [Related]
8. COX-2 overexpression increases malignant potential of human glioma cells through Id1.
Xu K; Wang L; Shu HK
Oncotarget; 2014 Mar; 5(5):1241-52. PubMed ID: 24659686
[TBL] [Abstract][Full Text] [Related]
9. Recurrent epimutations activate gene body promoters in primary glioblastoma.
Nagarajan RP; Zhang B; Bell RJ; Johnson BE; Olshen AB; Sundaram V; Li D; Graham AE; Diaz A; Fouse SD; Smirnov I; Song J; Paris PL; Wang T; Costello JF
Genome Res; 2014 May; 24(5):761-74. PubMed ID: 24709822
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral Heterogeneity of the Epigenome.
Mazor T; Pankov A; Song JS; Costello JF
Cancer Cell; 2016 Apr; 29(4):440-451. PubMed ID: 27070699
[TBL] [Abstract][Full Text] [Related]
11. A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer.
Liu Y; Wu Z; Zhou J; Ramadurai DKA; Mortenson KL; Aguilera-Jimenez E; Yan Y; Yang X; Taylor AM; Varley KE; Gertz J; Choi PS; Cherniack AD; Chen X; Bass AJ; Bailey SD; Zhang X
Nat Commun; 2021 Dec; 12(1):7139. PubMed ID: 34880227
[TBL] [Abstract][Full Text] [Related]
12. The role of m6A-modified CircEPHB4 in glioma pathogenesis: Insights into cancer stemness metastasis.
Liao Y; Qiu X; Liu J; Zhang Z; Liu B; Jin C
Ann Clin Transl Neurol; 2023 Oct; 10(10):1749-1767. PubMed ID: 37614011
[TBL] [Abstract][Full Text] [Related]
13. Prognostic model for assessing the human glioma cell malignancy grade based on MDM2, MELK, SOX2, CDK4, DR5 and OCT4 gene expression.
Tyagunova EE; Drozd SF; Kalennik OV; Samoylenkova NS; Savchenko EA; Danilov GV; Pavlova GV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(6):43-51. PubMed ID: 38054226
[TBL] [Abstract][Full Text] [Related]
14. Application of a novel strategy of engineering conditional alleles to a single exon gene, Sox2.
Mandalos N; Saridaki M; Harper JL; Kotsoni A; Yang P; Economides AN; Remboutsika E
PLoS One; 2012; 7(9):e45768. PubMed ID: 23029233
[TBL] [Abstract][Full Text] [Related]
15. 5-azacytidine inhibits Sox2 promoter methylation during the induction of Thy-1
Guo L; Jiang H; Lu Y; Liu M; Liu H
Am J Transl Res; 2023; 15(12):6718-6726. PubMed ID: 38186987
[TBL] [Abstract][Full Text] [Related]
16. Stem Cell Markers in Neoplasms and their Relationship with Progression-free and Overall Survival in Patients with Recurrence.
Eguiluz-Melendez A; Rubio-Osornio C; Rosiles-Abonce A; Mendoza C; Ramírez-Ordás M; Rivera-Cañas R; Tena-Suck M; Gómez-Amador JL; Moreno-Jimenez S
Recent Pat Anticancer Drug Discov; 2024 May; ():. PubMed ID: 38756074
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerability.
Drexler R; Khatri R; Sauvigny T; Mohme M; Maire CL; Ryba A; Zghaibeh Y; Dührsen L; Salviano-Silva A; Lamszus K; Westphal M; Gempt J; Wefers AK; Neumann J; Bode H; Hausmann F; Huber TB; Bonn S; Jütten K; Delev D; Weber KJ; Harter PN; Onken J; Vajkoczy P; Capper D; Wiestler B; Weller M; Snijder B; Buck A; Weiss T; Keough MB; Ni L; Monje M; Silverbush D; Hovestadt V; Suvà ML; Krishna S; Hervey-Jumper SL; Schüller U; Heiland DH; Hänzelmann S; Ricklefs FL
bioRxiv; 2023 Aug; ():. PubMed ID: 37609137
[TBL] [Abstract][Full Text] [Related]
18. Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and epigenetic regulators.
Bulstrode H; Johnstone E; Marques-Torrejon MA; Ferguson KM; Bressan RB; Blin C; Grant V; Gogolok S; Gangoso E; Gagrica S; Ender C; Fotaki V; Sproul D; Bertone P; Pollard SM
Genes Dev; 2017 Apr; 31(8):757-773. PubMed ID: 28465359
[TBL] [Abstract][Full Text] [Related]
19. SOX2 and cancer: current research and its implications in the clinic.
Weina K; Utikal J
Clin Transl Med; 2014; 3():19. PubMed ID: 25114775
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Garros-Regulez L; Aldaz P; Arrizabalaga O; Moncho-Amor V; Carrasco-Garcia E; Manterola L; Moreno-Cugnon L; Barrena C; Villanua J; Ruiz I; Pollard S; Lovell-Badge R; Sampron N; Garcia I; Matheu A
Expert Opin Ther Targets; 2016; 20(4):393-405. PubMed ID: 26878385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
